Business Dynamics: How Novo Nordisk Lost GLP-1 ...

By Rene Pretorius

June 2, 2025

The GLP-1 drug market, vital for diabetes and obesity treatments, is undergoing a seismic shift—most notably Novo Nordisk GLP-1 market share loss to rising competitors like Eli Lilly. This article unpacks the key

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.